These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 36833444)

  • 21. Ron receptor-dependent gene regulation of Kupffer cells during endotoxemia.
    Kulkarni RM; Stuart WD; Waltz SE
    Hepatobiliary Pancreat Dis Int; 2014 Jun; 13(3):281-92. PubMed ID: 24919612
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RON (
    Hunt BG; Jones A; Lester C; Davis JC; Benight NM; Waltz SE
    Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626096
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness.
    Maggiora P; Lorenzato A; Fracchioli S; Costa B; Castagnaro M; Arisio R; Katsaros D; Massobrio M; Comoglio PM; Flavia Di Renzo M
    Exp Cell Res; 2003 Aug; 288(2):382-9. PubMed ID: 12915129
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatocyte growth factor-like protein is a positive regulator of early mammary gland ductal morphogenesis.
    Gurusamy D; Ruiz-Torres SJ; Johnson AL; Smith DA; Waltz SE
    Mech Dev; 2014 Aug; 133():11-22. PubMed ID: 25049204
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The prostate transglutaminase, TGase-4, coordinates with the HGFL/MSP-RON system in stimulating the migration of prostate cancer cells.
    Jiang WG; Ye L; Ablin RJ; Kynaston HG; Mason MD
    Int J Oncol; 2010 Aug; 37(2):413-8. PubMed ID: 20596668
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Macrophage-stimulating protein, the ligand for the stem cell-derived tyrosine kinase/RON receptor tyrosine kinase, inhibits IL-12 production by primary peritoneal macrophages stimulated with IFN-gamma and lipopolysaccharide.
    Morrison AC; Wilson CB; Ray M; Correll PH
    J Immunol; 2004 Feb; 172(3):1825-32. PubMed ID: 14734766
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The macrophage stimulating protein/Ron pathway as a potential therapeutic target to impede multiple mechanisms involved in breast cancer progression.
    Kretschmann KL; Eyob H; Buys SS; Welm AL
    Curr Drug Targets; 2010 Sep; 11(9):1157-68. PubMed ID: 20545605
    [TBL] [Abstract][Full Text] [Related]  

  • 28. β-Catenin is required for Ron receptor-induced mammary tumorigenesis.
    Wagh PK; Gray JK; Zinser GM; Vasiliauskas J; James L; Monga SP; Waltz SE
    Oncogene; 2011 Aug; 30(34):3694-704. PubMed ID: 21423209
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recepteur d'origine nantais tyrosine kinase is a direct target of hypoxia-inducible factor-1alpha-mediated invasion of breast carcinoma cells.
    Thangasamy A; Rogge J; Ammanamanchi S
    J Biol Chem; 2009 May; 284(21):14001-10. PubMed ID: 19307182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression.
    Thomas RM; Toney K; Fenoglio-Preiser C; Revelo-Penafiel MP; Hingorani SR; Tuveson DA; Waltz SE; Lowy AM
    Cancer Res; 2007 Jul; 67(13):6075-82. PubMed ID: 17616662
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Met interacts with EGFR and Ron in canine osteosarcoma.
    McCleese JK; Bear MD; Kulp SK; Mazcko C; Khanna C; London CA
    Vet Comp Oncol; 2013 Jun; 11(2):124-39. PubMed ID: 22235915
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tyrosine kinase receptor RON and its ligand MSP in Merkel cell carcinoma.
    Nagahama J; Daa T; Yada N; Kashima K; Fujiwara S; Saikawa T; Yokoyama S
    Pathol Res Pract; 2011 Aug; 207(8):463-7. PubMed ID: 21723047
    [TBL] [Abstract][Full Text] [Related]  

  • 33. When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?
    Baird AM; Easty D; Jarzabek M; Shiels L; Soltermann A; Klebe S; Raeppel S; MacDonagh L; Wu C; Griggs K; Kirschner MB; Stanfill B; Nonaka D; Goparaju CM; Murer B; Fennell DA; O'Donnell DM; Barr MP; Mutti L; Reid G; Finn S; Cuffe S; Pass HI; Opitz I; Byrne AT; O'Byrne KJ; Gray SG
    Front Endocrinol (Lausanne); 2019; 10():89. PubMed ID: 30863365
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ribosomal protein S6 kinase (RSK)-2 as a central effector molecule in RON receptor tyrosine kinase mediated epithelial to mesenchymal transition induced by macrophage-stimulating protein.
    Ma Q; Guin S; Padhye SS; Zhou YQ; Zhang RW; Wang MH
    Mol Cancer; 2011 May; 10():66. PubMed ID: 21619683
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Receptor tyrosine kinase Ron is expressed in mouse reproductive tissues during embryo implantation and is important in trophoblast cell function.
    Hess KA; Waltz SE; Chan EL; Degen SJ
    Biol Reprod; 2003 Apr; 68(4):1267-75. PubMed ID: 12606483
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of MSP-RON signaling pathway in cancer cells by a novel soluble form of RON comprising the entire sema sequence.
    Ma Q; Zhang K; Yao HP; Zhou YQ; Padhye S; Wang MH
    Int J Oncol; 2010 Jun; 36(6):1551-61. PubMed ID: 20428780
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activation of the RON receptor tyrosine kinase by macrophage-stimulating protein inhibits inducible cyclooxygenase-2 expression in murine macrophages.
    Zhou YQ; Chen YQ; Fisher JH; Wang MH
    J Biol Chem; 2002 Oct; 277(41):38104-10. PubMed ID: 12177064
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Functional consequences of the macrophage stimulating protein 689C inflammatory bowel disease risk allele.
    Kauder SE; Santell L; Mai E; Wright LY; Luis E; N'Diaye EN; Lutman J; Ratti N; Sa SM; Maun HR; Stefanich E; Gonzalez LC; Graham RR; Diehl L; Faubion WA; Keir ME; Young J; Chaudhuri A; Lazarus RA; Egen JG
    PLoS One; 2013; 8(12):e83958. PubMed ID: 24409221
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Ron receptor tyrosine kinase activates c-Abl to promote cell proliferation through tyrosine phosphorylation of PCNA in breast cancer.
    Zhao H; Chen MS; Lo YH; Waltz SE; Wang J; Ho PC; Vasiliauskas J; Plattner R; Wang YL; Wang SC
    Oncogene; 2014 Mar; 33(11):1429-37. PubMed ID: 23542172
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Point mutations in the tyrosine kinase domain release the oncogenic and metastatic potential of the Ron receptor.
    Santoro MM; Penengo L; Minetto M; Orecchia S; Cilli M; Gaudino G
    Oncogene; 1998 Aug; 17(6):741-9. PubMed ID: 9715276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.